Compare Acadia Healthcare Company Inc (ACHC) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs BioNTech SE - ADR — how do they compare? Acadia Healthcare Company Inc trades at $31.14 (market cap $2.90B), while BioNTech SE - ADR trades at $92.82 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 8× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ACHC | BNTX | |
|---|---|---|
Market Cap | $2.90B | $23.31B |
Sector | Health | Health |
52-Week High | $35.61 | $119.34 |
52-Week Low | $11.68 | $83.89 |
Enterprise Value | $5.29B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.14, down 2.01% today, with a neutral technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains a net loss of -$1.10B for 2025. Analyst consensus is bullish with a $36.00 price target, though ongoing legal investigations and negative profit margins present headwinds. Cash flow from operations improved to $211M in 2026, supporting operational stability amid challenges.
The outlook for ACHC hinges on execution of its turnaround strategy and resolution of legal issues. Upside potential exists if EBITDA guidance improvements and admissions growth persist, but risks from litigation and sustained losses warrant caution. The stock's current valuation at a P/E of 19.82 and P/S of 0.84 may attract value investors if profitability recovers.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
